首页> 外文期刊>Clinical proteomics. >CSF extracellular vesicle proteomics demonstrates altered protein homeostasis in amyotrophic lateral sclerosis
【24h】

CSF extracellular vesicle proteomics demonstrates altered protein homeostasis in amyotrophic lateral sclerosis

机译:CSF细胞外囊泡蛋白质组学证明了肌萎缩侧面硬化症中的改变的蛋白质稳态

获取原文
       

摘要

Extracellular vesicles (EVs) released by neurons and glia reach the cerebrospinal fluid (CSF). Studying the proteome of CSF-derived EVs offers a novel perspective on the key intracellular processes associated with the pathogenesis of the neurodegenerative disease amyotrophic lateral sclerosis (ALS) and a potential source from which to develop biomarkers. CSF EVs were extracted using ultrafiltration liquid chromatography from ALS patients and controls. EV size distribution and concentration was measured using nanoparticle tracking analysis and liquid chromatography-tandem mass spectrometry proteomic analysis performed. CSF EV concentration and size distribution did not differ between ALS and control groups, nor between a sub-group of ALS patients with or without an associated hexanucleotide repeat expansion (HRE) in C9orf72. Univariate proteomic analysis identified downregulation of the pentameric proteasome-like protein Bleomycin hydrolase in ALS patients, whilst Gene Ontology enrichment analysis demonstrated downregulation of proteasome core complex proteins (8/8 proteins, normalized enrichment ratio -1.77, FDR-adjusted p?=?0.057) in the ALS group. The sub-group of ALS patients associated with the C9orf72 HRE showed upregulation in Ubiquitin-like modifying-activating protein 1 (UBA1) compared to non-C9orf72 cases. Proteomic analysis of CSF EVs in ALS detects intracellular alterations in protein homeostatic mechanisms, previously only identified in pathological tissues. This supports the wider use of CSF EVs as a source of novel biomarkers reflecting key and potentially druggable pathological intracellular pathway alterations in ALS.
机译:神经元和胶质胶释放的细胞外囊泡(EVS)到达脑脊液(CSF)。研究CSF衍生的EV的蛋白质组在与神经退行性疾病肌萎缩侧硬化症(ALS)发病机制相关的关键细胞内方法中提供了一种新的观点,以及从中开发生物标志物的潜在来源。使用来自ALS患者和对照的超滤液相色谱法提取CSF EV。使用纳米颗粒跟踪分析和液相色谱 - 串联质谱蛋白质组学分析测量EV尺寸分布和浓度。 CSF EV浓度和尺寸分布在ALS和对照组之间没有差异,或者在C9ORF72中没有相关的己核苷酸重复膨胀(HRE)的ALS患者的亚组之间。单变量蛋白质组学分析确定了ALS患者中的五聚体蛋白质样蛋白质博来霉素水解酶的下调性,但基因本体富集分析表明了蛋白酶体核心复合蛋白的下调(8/8蛋白,归一化富集比-1.77,FDR调整的P?= 0.057 )在ALS组中。与非C9ORF72病例相比,与C9ORF72 HRE相关的ALS患者的亚患者患有Ubiquitin的改性活化蛋白1(UBA1)的上调。 ALS中CSF EVS的蛋白质组学分析检测蛋白质稳态机制的细胞内改变,以前仅在病理组织中鉴定。这支持更广泛地使用CSF EV,作为反映ALS中的钥匙和潜在可用的病理细胞内途径改变的新型生物标志物的来源。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号